Suppressive Activity of Pemirolast Potassium, an Antiallergic Drug, on Glomerulonephritis

Abstract

Background:

It is still difficult to manage chronic glomerulonephritis with corticosteroids because of safety concerns, especially for patients with mild symptoms and infants. Therefore, an alternative approach is greatly required. Pemirolast potassium (CAS 100299-08-9) is an antiallergic drug with high safety.

Methods:

Two glomerulonephritis rat models were prepared to examine the pharmacological actions of pemirolast potassium: one reversible model prepared with the anti-Thy-1 antibody, and another irreversible model by unilateral nephrectomy and with the anti-Thy-1 antibody. Pemirolast potassium was administered to 10 Japanese chronic glomerulonephritis patients concurrently affected by allergic rhinitis in order to examine its efficacy for mild proteinuria.

Results:

Pemirolast potassium 1 and 10 mg/kg markedly inhibited proteinuria in the reversible model. In the irreversible model, pemirolast potassium 3 mg/kg showed a significant decrease in the incidence of glomerulosclerosis. In chronic glomerulonephritis patients, pemirolast potassium, 10 mg twice daily, for 6 months, significantly reduced the severity of proteinuria.

Conclusion:

Our research suggested the efficacy of pemirolast potassium in glomerulonephritis. A well-controlled study is considered necessary to validate pemirolast potassium as a therapeutic drug for glomerulonephritis.

Key words

Alegysal® - Antiallergic drugs - CAS 100299-08-9 - Glomerulonephritis, anti-Thy-1 antibody, experimental - Pemirolast potassium, efficacy in glomerulonephritis - Steroids

• References

• 1 Uzu T, Harada T, Ko M, Yamato M, Takahara K, Yamauchi A. Effect of corticosteroid therapy on the progression of IgA nephropathy with moderate proteinuria. Clin Exp Nephrol. 2003; 7: 210-214
• 2 Nolin L, Courteau M. Management of IgA nephropathy. evidence-based recommendations. Kidney Int.. (Suppl. 999) 70: S56-62
• 3 Katafuchi R, Ikeda K, Mizumasa T, Tanaka H, Ando T, Ya-nase T et al. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis. 2003; 41: 972-983
• 4 Kawashima T, Iwamoto I, Nakagawa N, Tomioka H, Yoshida S. Inhibitory effect of pemirolast, a novel antiallergic drug, on leukotriene C4 and granule protein release from human eosinophils. Int Arch Allergy Appl Immunol. 1994; 103: 405-409
• 5 Kawashima T, Matsui W. Inhibitory effect of TBX on leukocytes Emigration into pouch fluids in air-pouch allergic reaction. Jpn Pharmacol Ther. 1995; 23: 117-120
• 6 Miyazawa N, Umemura K, Kondo K, Nakashima M. Effects of pemirolast and tranilast on intimai thickening after arterial injury in the rat. J Cardiovasc Pharmacol. 1997; 30: 157-162
• 7 Ohsawa H, Noike H, Kanai M, Yoshinuma M, Mineoka K, Hitsumoto T et al. Preventive effects of an antiallergic drug, pemirolast potassium, on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J. 1998; 136: 1081-1087
• 8 Takishima T., Shirato K., Tamura G.. Med. Cons. New Remed. Post-marketing surveillance of pemirolast potassium (TBX) in adult bronchial asthma. Med Cons New Remed. 1994; 31: 2039-2052
• 9 Nakamura T, Obata I, Kimura H, Ohno S, Yoshida Y, Kawachi H et al. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int. 1999; 55: 877-839
• 10 lefferson JA, Johnson RJ. Experimental mesangial proliferative glomerulonephritis (the anti-Thy-1.1 model). I Nephrol. 1999; 12: 297-307
• 11 Nagata M, Nagata T, Onimaru T, Tanaka K, Ohnishi M, Kakimoto D et al. 13-Week oral subacute toxicity studies followed by 5-week recovery test of TBX in beagles. Jpn Pharmacol Ther. 1989; 17: 1153-1181
• 12 Nagata M, Nagata T, Onimaru T, Tanaka K, Ohnishi M, Kakimoto D et al. Chronic toxicity study of TBX in beagles administered orally for 52 weeks. Jpn Pharmacol Ther. 1989; 17: 1183-1204
• 13 Watanabe M, Kanitani M, Kobayashi Y, Taki M, Minematsu S, Maemura S et al. Combined effect of glucocorticoid and TJ-114 (Tsumura Sairei-to). Nippon Yakurigaku Zasshi. 1993; 101: 39-51
• 14 Belvisi MG, Wicks SL, Battram CH, Bottoms SE, Redford IE, Woodman P et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of tran-srepression from transactivation activity. J Immunol. 2001; 166: 1975-1982
• 15 Lai KN, Lai FM, Ho CR, Chan KW. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol. 1986; 26: 174-180
• 16 Welch TR, Fryer C, Shely E, Witte DP, Quinlan M. Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis. J Pediatr. 1992; 121: 474-477
• 17 Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli D et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999; 353: 883-887
• 18 Steel RGD. A multiple comparison rank sum test: Treatment versus control. Biometrics. 1959; 15: 560-572